Table 1. Arsenic trioxide (ATO) in newly... | American Society of Hematology

Table 1.

Arsenic trioxide (ATO) in newly diagnosed acute promyelocytic leukemia (APL).

	Author	N	CR, %	Postremission PCR neg, %	Therapy	EFS, %	OS, %
* disease-free survival
**96% in low-risk, 78.9% in high-risk
†RFS, relapse-free survival
‡ 94 of the 111 patients were newly diagnosed
§ For patients in complete remission
Abbreviations: ATRA, all-trans retinoic acid
ATO + ATRA	Liu³⁷	60	93.3	NR	Chemo ± ATRA	94.2 at 4 y*	98 at 4 y
	Estey³⁸	44	88.6**	100	ATRA + ATO	90 at 2 y†	90 at 2 y
ATO as a Single Agent	Ghavamzadeh³⁹	111‡	85.6	92	ATO × 1	63.7 at 2 y	87.6 at 3 y§
	Mathews⁴⁰	72	86	76	ATO × 6	74.8 at 3 y	86.1 at 3 y
	George⁴¹	11	91	100	ATO	813 at 5 y	91 at 5 y

	Author	N	CR, %	Postremission PCR neg, %	Therapy	EFS, %	OS, %
* disease-free survival
**96% in low-risk, 78.9% in high-risk
†RFS, relapse-free survival
‡ 94 of the 111 patients were newly diagnosed
§ For patients in complete remission
Abbreviations: ATRA, all-trans retinoic acid
ATO + ATRA	Liu³⁷	60	93.3	NR	Chemo ± ATRA	94.2 at 4 y*	98 at 4 y
	Estey³⁸	44	88.6**	100	ATRA + ATO	90 at 2 y†	90 at 2 y
ATO as a Single Agent	Ghavamzadeh³⁹	111‡	85.6	92	ATO × 1	63.7 at 2 y	87.6 at 3 y§
	Mathews⁴⁰	72	86	76	ATO × 6	74.8 at 3 y	86.1 at 3 y
	George⁴¹	11	91	100	ATO	813 at 5 y	91 at 5 y